Systematic review: colitis associated with anti-CTLA-4 therapy

Area of Science:

• Immunology
• Gastroenterology
• Oncology

Background:

• Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) plays a key role in T-cell regulation and tolerance.
• Anti-CTLA-4 agents like ipilimumab and tremelimumab show promise in treating metastatic melanoma and other cancers.
• These therapies can lead to immune-related adverse effects, particularly gastrointestinal issues such as diarrhea and colitis.

Purpose of the Study:

• To review the literature on anti-CTLA-4-associated colitis.
• To summarize the epidemiology, pathogenesis, and clinical features of this condition.
• To propose a management algorithm for anti-CTLA-4-associated colitis.

Main Methods:

• A literature search was conducted on PubMed up to October 2014.
• Keywords included 'anti-CTLA,' 'ipilimumab,' 'tremelimumab,' 'colitis,' 'gastrointestinal,' 'immune-related adverse effect,' 'immunotherapy,' 'melanoma,' and 'diarrhea.'

Main Results:

• Watery diarrhea affects 27-54% of patients on anti-CTLA-4 therapy, typically appearing within weeks.
• Endoscopy reveals diffuse acute and chronic colitis in 8-22% of cases; infectious causes must be ruled out.
• Most cases respond to anti-CTLA-4 discontinuation and conservative treatment; persistent cases may require corticosteroids or anti-tumor necrosis factor-alpha therapy.

Conclusions:

• Clinicians must be aware of immune-related adverse events associated with anti-CTLA-4 therapy.
• Prompt recognition and appropriate management are crucial for patient outcomes.
• The use of anti-CTLA-4 agents necessitates vigilance for gastrointestinal toxicities.